De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer.

IF 1 Q4 ONCOLOGY

Current Breast Cancer Reports Pub Date : 2022-01-01 Epub Date: 2022-07-27 DOI:10.1007/s12609-022-00453-3

Marios-Konstantinos Tasoulis, Joerg Heil, Henry M Kuerer

{"title":"De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer.","authors":"Marios-Konstantinos Tasoulis, Joerg Heil, Henry M Kuerer","doi":"10.1007/s12609-022-00453-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple negative (TN) disease. The aim of this review is to discuss the recent data on de-escalation of surgery as well as the future directions.Recent findings: Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. Post-NACT image-guided biopsy, potentially combined with machine learning algorithms, may accurately identify patients achieving pathologic complete response that would be eligible for clinical trials assessing safety of omission of breast and axillary surgery.Summary: Multidisciplinary research is required to further support results of preliminary studies. Current data point towards a future when even less or no surgery may be required for exceptional responders.","PeriodicalId":10769,"journal":{"name":"Current Breast Cancer Reports","volume":"14 4","pages":"135-141"},"PeriodicalIF":1.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328618/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Breast Cancer Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12609-022-00453-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple negative (TN) disease. The aim of this review is to discuss the recent data on de-escalation of surgery as well as the future directions.

Recent findings: Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. Post-NACT image-guided biopsy, potentially combined with machine learning algorithms, may accurately identify patients achieving pathologic complete response that would be eligible for clinical trials assessing safety of omission of breast and axillary surgery.

Summary: Multidisciplinary research is required to further support results of preliminary studies. Current data point towards a future when even less or no surgery may be required for exceptional responders.

查看原文本刊更多论文

在 HER2 + 和三阴性乳腺癌患者中取消手术。

回顾的目的：手术降级一直是乳腺癌多学科治疗发展的核心。肿瘤学的发展和新辅助化疗（NACT）的应用日益广泛，为进一步降低手术等级提供了机会，尤其是针对 HER2 + 和三阴性（TN）疾病。本综述旨在讨论手术降级的最新数据以及未来的发展方向：最新研究结果：对 NACT 反应极佳的 TN 和 HER2 + 乳腺癌患者是手术降级的理想人选。NACT后的图像引导活检可能与机器学习算法相结合，可以准确识别出获得病理完全反应的患者，这些患者将有资格参与评估省略乳腺和腋窝手术安全性的临床试验。目前的数据表明，未来特殊应答者甚至可能只需较少或无需手术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Breast Cancer Reports ONCOLOGY-

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of breast cancer. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those with the disease. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as prevention, systemic therapy, and translational research. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.